Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.60 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.60 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5404017 | 0.92 | NPSR1 (0.55) | PTGS1PTGS2ALDH1A1LMNANPSR1 | |
| SCHEMBL5402527 | 0.90 | LMNA (0.50) | PTGS1PTGS2KCNA5ALDH1A1LMNA | |
| SCHEMBL5408875 | 0.89 | ALDH1A1 (0.48) | PTGS1PTGS2KCNA5ALDH1A1LMNA | |
| SCHEMBL5406373 | 0.88 | ALDH1A1 (0.50) | PTGS1PTGS2KCNA5ALDH1A1LMNA | |
| SCHEMBL5397992 | 0.87 | ALDH1A1 (0.48) | PTGS1PTGS2KCNA5ALDH1A1LMNA | |
| SCHEMBL5402969 | 0.86 | ALDH1A1 (0.50) | PTGS1PTGS2ALDH1A1LMNANPSR1 | |
| SCHEMBL5407258 | 0.84 | CACNA1B (0.54) | PTGS1PTGS2ALDH1A1LMNAGAA | |
| SCHEMBL5392578 | 0.83 | CACNA1B (0.55) | PTGS1PTGS2ALDH1A1LMNANPSR1 | |
| SCHEMBL5418655 | 0.81 | PTGS1 (0.51) | PTGS1PTGS2KCNA5ALDH1A1GAA | |
| SCHEMBL5156178 | 0.81 | NPSR1 (0.52) | PTGS1PTGS2ALDH1A1LMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7169782-B2 | Aryl substituted thiazolidinones and the use thereof | EURO-CELTIQUE S.A. (LU) | 2007-01-30 | — | — | US | claimed |
| US-20040176364-A1 | Aryl substituted thiazinidinones and the use thereof | EURO-CELTIQUE S.A. (LU) | 2004-09-09 | — | — | US | claimed |
| EP-1417187-A1 | ARYL SUBSTITUTED THIAZOLIDINONES AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2004-05-12 | — | — | EP | claimed |
| US-20030109521-A1 | Aryl substituted thiazolidinones and the use thereof | EURO-CELTIQUE, S.A. | 2003-06-12 | — | — | US | claimed |
| WO-2003008398-A1 | ARYL SUBSTITUTED THIAZOLIDINONES AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2003-01-30 | — | — | WO | claimed |
| US-7169782-B2 | Aryl substituted thiazolidinones and the use thereof | EURO-CELTIQUE S.A. (LU) | 2007-01-30 | — | — | US | disclosed |
| US-20040176364-A1 | Aryl substituted thiazinidinones and the use thereof | EURO-CELTIQUE S.A. (LU) | 2004-09-09 | — | — | US | disclosed |
| US-20030109521-A1 | Aryl substituted thiazolidinones and the use thereof | EURO-CELTIQUE, S.A. | 2003-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109521-A1 | Aryl substituted thiazolidinones and the use thereof | CACNA1S, CACNA1I, CACNA1C | PTGS1 789/4885PTGS2 1821/4885KCNA5 344/4885 |
| US-20040176364-A1 | Aryl substituted thiazinidinones and the use thereof | CACNA1S, CACNA1I, NLN | PTGS1 907/4885PTGS2 1921/4885KCNA5 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.